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Abstract
MicroRNA molecules are small, single-stranded RNA molecules that function to regulate 
networks of genes. They play important roles in normal female reproductive tract biology, as well 
as in the pathogenesis and progression of epithelial ovarian cancer. DROSHA, DICER, and 
Argonaute proteins are components of the microRNA-regulatory machinery and mediate 
microRNA production and function. This review discusses aberrant expression of microRNA 
molecules and microRNA-regulating machinery associated with clinical features of epithelial 
ovarian cancer. Understanding the regulation of microRNA molecule production and function may 
facilitate the development of novel diagnostic and therapeutic strategies to improve the prognosis 
of women with epithelial ovarian cancer. Additionally, understanding microRNA molecules and 
microRNA-regulatory machinery associations with clinical features may influence prevention and 
early detection efforts.
1. Introduction
Ovarian cancer is the most lethal gynecologic malignancy and will claim more than 14,000 
lives in 2017 in the United States (1). Epithelial ovarian cancer (EOC) is the most prevalent 
type of ovarian cancer, accounting for 90% of all ovarian cancers. It is characterized by 
distinct histological phenotypes including serous, endometrioid, clear-cell, and mucinous. 
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Each histotype is thought to arise from distinct precursor lesions of the female reproductive 
tract (2). Molecularly, the landscape of each individual EOC histotype is distinct at the gene 
expression and genomic DNA level, allowing novel means to classify tumors beyond 
traditional histology (3, 4).
Early stage EOC has a 5-year survival of 92%, while late stage disease has a 5-year survival 
of only 29%. Unfortunately, 79% of women with EOC have late stage disease, defined as 
regional or distant metastasis, based on SEER data from 2006–2012 (1). Improved screening 
approaches to detect early stage disease and novel histotype- or molecular-marker specific 
therapies for the treatment of late stage disease are urgently needed. This review highlights 
clinical associations of microRNA molecules and microRNA machinery, including 
DROSHA, DICER, and Argonaute proteins, in EOC identified since our last review (5). The 
clinical relevance of these potential new biomarkers as prognostic, diagnostic, and 
therapeutic molecules are discussed.
2. Genesis of Mature MicroRNA Molecules
a. MicroRNA-Regulating Machinery
RNA polymerase II transcribes microRNA molecules from genomic DNA into a primary 
microRNA molecule (pri-miRNA). Pri-miRNA molecules are typically greater than 200 
nucleotides in length with a characteristic stem loop structure. Furthermore, microRNA 
clusters containing multiple stem loop structures, each coding for a mature microRNA 
molecule, can be in the kilobase size range. Pri-miRNA molecules are recognized by 
DROSHA, an RNAse III, which cuts the double-stranded RNA into ~70-nucleotide 
precursor microRNA (pre-miRNA) in the nucleus. Pre-miRNA molecules are exported to 
the cytoplasm and are processed by DICER, an RNAse III, into two unique single-stranded 
mature microRNA molecules representing each side of the stem loop structure. Mature 
microRNA molecules are loaded onto the Argonaute-containing RNA-induced silencing 
complex (RISC). Within this structure, mature microRNA molecules function to repress 
gene expression by complementary binding of the 3’ untranslated region (UTR) of the target 
gene to the miRNA seed sequence, nucleotides 2–8 of the mature miRNA molecule, leading 
to transcript degradation, and subsequent gene product loss (6). Studies have shown that 
microRNA-target genes play an important role in EOC cancer biology (7). Thus, microRNA 
molecules and their biogenesis regulation as mediated by microRNA machinery is clinically 
important.
b. Primer on MicroRNA Nomenclature
Understanding how microRNA molecules are named is important for understanding how 
closely related microRNA molecules are to each other in the context of clinical associations 
and molecular functions. MicroRNA molecules are sequentially named as they are 
discovered. For example, miR-21 was discovered and annotated in miRBase prior to 
miR-1307. Identical mature microRNA molecules of identical sequence may originate from 
different genomic loci with different primary microRNA molecule sequence due to the RNA 
processing. For example, miR-196a-1 and miR-196a-2 have identical mature microRNA 
sequence but originate from different genomic locations (i.e., chromosome 17 versus 
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chromosome 12). This is different from microRNA molecules that have a closely related 
mature microRNA sequence such as miR-10a and miR-10b, which have a different mature 
sequence and are derived from different genomic locations. MiR-10a-5p and miR-10b-5p 
share the same seed sequence but different in one nucleotide in the mature sequence (8).
DICER processes each precursor microRNA into two mature molecules, with reverse 
complement sequence. Traditionally, the microRNA molecule with the greatest abundance 
was assigned the microRNA name (i.e., miR-29c), while the mature microRNA molecule on 
the other arm was called the * form (i.e., miR-29c*) (8). This nomenclature, based on 
abundance, was phased out, and a new nomenclature, based on the location of the mature 
microRNA on the 5’ or 3’ strand, was phased in. Thus, the miRNA-3p forms are not 
necessarily less abundant or less functional. The nomenclature is now based on sequence 
location on the stem look. Mature microRNA molecules are grouped into families based on 
identical seed sequence, which are nucleotides 2–8 of the mature molecule. This sequence 
serves to function in complementary binding to the 3’UTR, leading to downstream effects of 
transcript repression (8). MiRNA-5p and miRNA-3p molecules do not typically fall within 
the same microRNA family as they have a reverse complementary sequence. For example, 
the miR-10-5p family is comprised of miR-10a-5p and miR-10b-5p while miR-10a-3p and 
miR-10b-3p are each members of their own family. Finally, isomiRs are mature microRNA 
molecules that differ from the mature sequence by 1–2 nucleotides. For example, the 
miR-21+CA isomiR is formed from a unique tailing and trimming mechanism in 
proliferative diseases such as endometriosis and endometrial cancer. It contains the miR-21 
mature sequence plus an additional two nucleotides (9). While isomiRs have not yet been 
described in EOC, these unique molecules represent an opportunity to be utilized as 
biomarkers.
3. Clinical Implications
a. Aberrant Expression of MicroRNA-Biogenesis Machinery Components in EOC
Multiple studies have examined the relative expression of DICER and DROSHA in EOC 
compared to control tissues. Choice of control tissue for comparison is critical in relative 
expression studies. Each histotype of ovarian cancer may arise from distinct precursor cells 
(2). For example, high-grade serous EOC may arise from the fallopian tube or ovarian 
surface epithelium (10–12). Endometrioid and clear-cell EOC may arise from a benign 
transformation of endometriosis (13, 14). For these reasons, we will define histotype and 
control tissues used for each study.
Using 50 cases of high-grade serous ovarian cancer, Flavin et al (15) revealed a significant 
upregulation of DROSHA and a trend towards upregulation in DICER by QPCR compared 
to normal ovary. Similarly, by immunohistochemistry in 37 samples, DICER showed a 
significant upregulation in high-grade serous ovarian cancer. High DICER expression was 
associated with an absence of lymph node metastasis and a low proliferation index. DICER 
expression did not correlate with disease free or overall survival (15). The authors did not 
comment on DROSHA expression by immunohistochemistry, nor did they comment on the 
association of DROSHA with clinical factors. Additionally, only high-grade serous EOC 
tumor samples were examined.
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Merritt et al (16) examined DICER and DROSHA in 111 samples of EOC (2 endometrioid, 
109 serous, 93 high grade, 18 low grade) by QPCR with validation by 
immunohistochemistry. Benign ovarian surface epithelium was used as a control. Using the 
bimodal expression of DICER and DROSHA in their dataset to classify tumors into low and 
high expression for DICER and DROSHA, they examined clinical associations. Low DICER 
expression was associated with advanced-stage disease and reduced median survival. Low 
DROSHA expression was associated with suboptimal cytoreduction and reduced median 
survival. Death from ovarian cancer was statistically associated with low levels of both 
DICER and DROSHA while high levels of both DICER and DROSHA were associated with 
increased median survival. Low DICER was a predictor of poor prognosis (hazard ratio, 
2.10; 95% CI, 1.15 to 3.85) but low DROSHA was not. However, low DICER and low 
DROSHA was a predictor of death (hazard ratio, 4.00; 95% CI, 1.82 to 9.09). Cells with low 
DICER expression could not process shRNA, an important potential therapeutic 
consideration (16). A similar study using semi-quantitative RT PCR showed that DICER 
expression was downregulated in both benign and malignant ovarian tumors compared to 
normal ovary. However, the specific histotype of malignant ovarian tumors was not defined 
(17).
DICER expression was evaluated by immunohistochemistry in a large tissue microarray 
containing 87 serous and 39 non-serous ovarian tumors. DICER expression negatively 
correlated with node status and tumor grade. Low DICER expression in serous tumors was 
associated with poor overall survival. A similar trend was found for all tumors in the dataset 
but the analysis was not performed for specific histotypes. MicroRNA profiling in tumors 
with low DICER showed significant downregulation of many microRNA molecules 
compared to tumors with high DICER expression. Additionally, tumors with low DICER 
expression also had low estrogen receptor expression (18). Zhang et al (19) did not find any 
significant difference in DICER or DROSHA expression by QPCR or 
immunohistochemistry staining between early and late stage disease without evaluation of 
normal control tissues, although there were differences in microRNA expression levels (19).
Flavin et al (15) showed an association of high DICER expression associated with better 
prognosis tumors (i.e., low metastatic lesions, low proliferative index tumors) but did not 
comment on low DICER expression being associated with poor prognosis tumors per se 
(15). Others have shown an association of poor survival with low expression of DICER (16, 
18). However, Flavin et al did not find a significant association of DICER expression with 
survival rates (15). Clinical associations for DICER expression are intriguing for EOC. 
However, studies within the breast cancer literature have shown divergent expression results 
using different DICER antibodies based on hormone receptor status of the tissues (20). 
Additionally, each study in EOC determined a relative cut off value for “low” and “high” 
DICER expression. Prior to use of DICER expression in clinical care, these differences in 
cut off values and antibody use must be standardized.
A meta-analysis showed an overall association of low DICER expression with poor 
prognosis in multiple cancer types including ovarian cancer (21). Lower expression of 
microRNA machinery is associated with poor prognosis tumors, suggesting that global loss 
of microRNA regulation may underlie the pathophysiology of poor prognosis EOC. These 
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studies suggest that loss of DICER may act as loss of a tumor suppressor, leading to disease 
that is more aggressive. Finally, these studies also suggest that lack of DICER may influence 
attempts to treat tumors with small RNA molecules such as shRNA molecules.
Examination of expression of DICER, DROSHA, Argonaute 1 (AGO1), and Argonaute 2 
(AGO2) in serous ovarian cancer revealed higher expression in metastatic lesions – either 
solid metastatic lesions or effusions – compared to the primary tumor (22). Thus, high levels 
of microRNA machinery may be required for disease progression.
b. Aberrant MicroRNA-Regulating Machinery Expression in Mouse Models
MicroRNA-regulating machinery is required for appropriate development of the female 
reproductive tract, as studies from mice have shown that full deletion of Dicer or Ago2 leads 
to embryonic lethality (23, 24). Conditional deletion of Dicer or Ago2, allowing for 
postnatal studies with targeted deletion to the female reproductive tract using genetically 
engineered mouse models, revealed defects in female fertility (25). However, deletion of 
Drosha in mice does not affect fertility or female reproductive tract development (25). 
Importantly, none of these models result in a cancer phenotype, suggesting a critical role in 
normal female reproductive tract development and function, but not cancer initiation in the 
mouse, and thus, Dicer is not likely a true tumor suppressor.
Notably, loss of Dicer is critical to the development of high-grade serous EOC that begins in 
the oviduct of the mouse but also requires phosphatase and tensin homolog (Pten) deletion. 
In terms of translational importance, the histology of the ovarian tumors from anti-Müllerian 
hormone receptor type 2-Cre recombinase (Amhr2Cre/+); Dicerflox/flox; Ptenflox/flox mice 
recapitulated high-grade serous tumors from women. When the oviducts of Amhr2Cre/+; 
Dicerf/f; Ptenf/f mice were removed, the mice failed to develop ovarian tumors. Thus, this 
model represents an important model to study the origins and mechanism of disease 
processes from the oviduct (10). However, a majority [~96% of the Cancer Genome Atlas 
(TCGA) population] of high-grade serous EOC tumors from women contain mutations in 
tumor protein 53 (TP53) (26). Addition of a TP53 mutation to the Amhr2Cre/+; Dicerf/f; 
Ptenf/f mice (Amhr2Cre/+; Dicerf/f; Ptenf/f; TP53R172H mice) with removal of oviduct 
revealed metastatic tumors arising from the ovary. However, loss of Dicer was not required 
as Amhr2Cre/+; Ptenf/f; TP53R172H mice developed similar metastatic lesions from the 
ovaries (12). Thus, loss of Dicer seems to be important for high-grade serous EOC arising 
from the oviduct but not for disease arising from the ovary. The role of specific cell types 
and specific genetic hits in the origin of EOC requires further study prior to translational 
extrapolation to disease in women.
Other genetically engineered mouse models of Dicer deletion have revealed that loss of two 
alleles of Dicer is protective against cancer development, while loss of one allele gives a 
more aggressive cancer phenotype. Specifically, conditional loss of one allele of Dicer had a 
faster rate of lung cancer formation on an oncogenic KRAS proto-oncogene, GTPase 
(KrasG12D) background, while loss of both Dicer alleles led to inhibition of tumor formation 
(27). Similarly, Dicer haploinsufficiency on an oncogenic B-Raf proto-oncogene, serine/
threonine kinase (Braf) (V600E) background led to increased metastasis in sarcomas (28). 
Loss of one allele of Dicer in the retinoblasts of mice led to aggressive retinoblastoma with 
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the inactivation of the retinoblastoma gene (29). Similarly, loss of one allele of Dicer with 
Pten in the prostate led to more aggressive tumors (30). These effects seem to be oncogene 
and tissue dependent, as conditional Dicer haploinsufficiency on an oncogenic MYC proto-
oncogene, bHLH transcription factor (c-Myc) background does not facilitate cancers in B 
cells (31). One hypothesis supported by in vitro studies is that loss of one allele of Dicer 
affects microRNA processing, or total expression of microRNA molecules, with loss of one 
allele of Dicer affecting the ratio of miRNA-5p to miRNA-3p from the precursor microRNA 
(32–34). Further studies are needed to determine the effects of DICER on microRNA 
processing in the initiation and progression of cancer in other female reproductive tract 
cancers, such as EOC.
c. Genetic Alterations of MicroRNA Machinery Genes
EOC is a genetically heterogeneous disease. Examination of copy number loss of DICER in 
TCGA datasets revealed frequent loss of DICER in high-grade serous EOC, consistent with 
low levels of expression and association with poor clinical outcome (10). However, DICER 
functional mutations are not recurrent in high-grade serous ovarian cancer (16, 35, 36). 
Liang et al (37) studied single nucleotide polymorphisms from 8 miRNA processing genes 
and 134 microRNA-binding sites in genes in 339 EOC cases and 349 healthy controls. This 
work revealed that polymorphisms in specific microRNA binding sites in genes were 
associated with cancer risk, overall survival, and treatment response. In particular, a 
homozygous polymorphism in platelet derived growth factor C (PDGFC) showed the most 
statistically significant effect on survival (37). Single nucleotide polymorphisms in 
DROSHA were found to be associated with an increased risk of EOC diagnosis in a mostly 
Caucasian study population (37), but this association was not significant in a larger more 
ethnically diverse population (38). Other studies have shown no association between 
polymorphisms in microRNA binding sites or mature microRNA molecules with EOC 
clinical outcomes (39–41). Thus, use of single nucleotide polymorphisms in microRNA 
machinery genes, mature microRNA molecules, or microRNA binding sites in genes to 
determine the risk of EOC diagnosis has been not been replicated clinically. Larger studies 
and grouping samples according to newly published genetic changes (4) instead of histotype 
or grade may allow for results that are more replicable.
4. MicroRNA Molecules as Clinical Biomarkers for EOC
a. MicroRNA Molecules with Clinical Associations
In recent years, comprehensive profiling studies have revealed that microRNA molecules 
have distinct patterns of expression in EOC (Supplemental Tables 1–2). A majority of these 
studies have used high-grade serous EOC or grouped all EOC histotypes together during 
analysis. The choice of the control group for comparison has differed across many studies. 
Additionally, the microRNA-profiling platform has also differed. Thus, it is not surprising 
that the reproducibility of some microRNA profiling datasets have been called into question, 
as the comparisons, samples, and technical platforms are not the same (42). Attention to 
these details will be critical to deciphering important biomarkers.
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Multiple studies have profiled microRNA molecules from clinical samples to determine if 
microRNA molecules would be good biomarkers for EOC (Supplemental Tables 1–2). Many 
of these large profiling studies aim to classify tumors into clinically important associations 
such as poor prognosis tumors, histotype, or chemotherapy responsive. Many of these 
studies do not limit samples to one particular histotype. Supplemental Tables 1 and 2 list the 
studies, brief details of experimental design including sample number, histotype, microRNA 
profiling platform, and validation sample set if applicable. There are 14 studies that use only 
serous histotype samples (Supplemental Table 1) and 13 studies that mix histotypes in the 
same study (Supplemental Table 2). Since our two previous reviews (5, 25), the published 
studies for comprehensive microRNA profiling studies in EOC have expanded greatly in 
number and sophistication of experimental design. Clinical associations of specific 
microRNA molecules in EOC tissues are listed in Supplemental Table 3. Thus, microRNA 
molecules hold promise for clinically useful biomarkers.
b. MicroRNA Molecules in Rare Histotypes of EOC
The molecular landscape of each histotype of EOC is distinct (3, 4). However, all patients 
are treated similarly with standard of care debulking surgery and chemotherapy regimens, 
with dismal “cure” rates of 20% (1). Notably, the presence of endometriosis, a benign 
pathologic growth of endometrium outside the uterus (43), leads to a 50% increase in the 
risk of ovarian cancer (44). Further, women with endometriosis are at higher risk of 
developing rare EOC subtypes, including clear-cell or endometrioid histotypes, as opposed 
to the more common high-grade serous disease (44). Therefore, a critical need exists to 
understand the genomic and pathophysiological differences between these histologic 
subtypes for early detection and for the development of histotype-specific therapies. Several 
studies have examined the role of microRNA molecules in these distinct EOC types.
MiR-132, miR-9, miR-126, miR-34a, and miR-21 were found to differentiate clear-cell from 
serous tumors. MiR-9, the most highly expressed of those five microRNA molecules in 
clear-cell samples, was found to be involved in cellular invasion in vitro (45). In a similar 
study, miR-510, miR-129-3p, miR-483 and miR-449a were found to be differentially 
expressed between serous and clear-cell ovarian tumors. All were associated with advanced 
tumor stage. Low expression of miR-129-3p or low expression of miR-510 was associated 
with poor overall survival (46). MiR-30a*, miR-30e* and miR-505* were the most 
upregulated miRNAs in clear-cell ovarian tumors compared with serous tumors (47). Lower 
expression of miR-30a*, miR-30e* and miR-505* were associated with poorer prognosis. 
Additionally, miR-134-3p was downregulated in CD44+/CD133+ ovarian cancer cells from 
clear-cell tumors. MiR-134-3p directly targeted RAB27A, which is involved in 
downregulation of stem cell markers and adhesions proteins (48). Overexpression of miR-21 
was associated with endometriosis in clear-cell ovarian cancer, and miR-21 targets the tumor 
suppressor PTEN (49). Thus, microRNA molecules play a functional role in the regulation 
of gene expression in clear-cell ovarian cancer differently than high-grade serous ovarian 
cancer.
As a potential clinically relevant serum biomarker, miR-130a is elevated in the serum of 
women prior to surgery for clear-cell ovarian cancer and falls after surgery. Additionally, 
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miR-130a levels increase prior to CA-125 levels prior to disease recurrence, making 
miR-130a a promising biomarker (50). This was a well-normalized study in a specific 
histotype of ovarian cancer in a specific ethnic population. The results are promising and 
need further study in benign disease, normal control women, and other histotypes. A 
similarly important study showed a minimal signature of microRNA molecules detected in 
blood and the ability to determine whether a woman had endometriosis, clear-cell, 
endometrioid, or serous ovarian cancer (51). Thus, the clinical usefulness of microRNA 
molecules as biomarkers for EOC, in particular, subtype-specific histotypes, has not been 
sufficiently studied.
Multiple studies have highlighted the function of microRNA molecules in terms of 
endometrioid histotypes (52–54). Expression of miR-191 was increased in ovarian 
endometriosis and endometrioid EOC. Importantly, miR-191 overexpression in vitro 
decreased tumor necrosis factor alpha- (TNFα) induced apoptosis (52). Given the high 
expression of TNFα in the pelvic cavity of women with endometriosis (55), the failure of 
apoptosis due to high miR-191 may play a role in the over proliferation of endometrioid 
EOC associated with endometriosis. Additionally, miR-191 directly targets TIMP 
metallopeptidase inhibitor 3 (TIMP3) and loss of miR-191 leads to decreased cellular 
proliferation and decreased invasion in vitro (53). Furthermore, miR-370 is downregulated in 
endometrioid EOC compared to the normal ovary or other histotypes of EOC. 
Overexpression of miR-370 in vitro showed decreased proliferation and increased sensitivity 
to platinum. Similar results were revealed in xenograft studies with miR-370 (54). Thus, 
microRNA molecules may play significant roles in the underlying biology of endometrioid 
EOC.
c. MicroRNA Molecules in Bodily Fluids as Biomarkers
MicroRNA molecules offer promise as molecules for early detection. Urinary excretion of 
miR-30a-5p is found in serous ovarian cancer but not in other cancer types. After primary 
debulking surgery, less expression of miR-30a-5p is found in the urine (56). While Zhou et 
al (56) did not examine the expression of miR-30a-5p after recurrence of ovarian cancer, this 
microRNA may serve as a useful biomarker for determination of disease. Langhe et al (57) 
used a discovery set of five malignant high-grade serous and five benign serous 
cystadenomas to examine the expression of microRNA levels in blood. They determined a 
significant downregulation of let-7i-5p, miR-122, miR-152-5p and miR-25-3p in malignant 
disease compared to benign disease state (57). Thus, microRNA molecules may serve as 
biomarkers for pre-operative discrimination of benign and malignant disease. Table 1 lists 
the clinically relevant microRNA molecules as biomarkers for EOC and their associated 
clinical features.
d. MicroRNA Molecules as Markers of Treatment Specificity
A strategic priority of the NCI Gynecologic Cancer Steering Committee is identification of 
molecular and/or pathologic cancer subsets to drive therapy and improve outcomes. A large 
well-normalized study examined outcomes and expression of microRNA molecules in the 
blood of women with EOC in ICON7. This study aimed at assessing the safety and efficacy 
of adding the anti-angiogenesis immunologic therapy, specifically bevacizumab, to standard 
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therapy. The isolation of microRNA molecules from blood was well described, and the 
experimental design contained a discovery and validation cohort. MiR-1274a, miR-141, 
miR-200b, and miR-200c were associated with survival in the discovery studies. MiR-141 
and miR-200b were similarly associated in the validation cohort containing all histotypes. 
MiR-200c was associated with better survival in women treated with bevacizumab compared 
to standard chemotherapy. Sub-classification of serous tumors revealed low miR-1274a 
associated with prolonged survival in discovery and validation groups (58). With the caveat 
that the study awaits independent replication, the results suggest the potential usefulness of 
miRNA profiles for the future choice of therapy regimens in EOC.
Petrillo et al (59) analyzed microRNA profiles from matched tumor samples before and after 
neoadjuvant chemotherapy. They found that samples collected after neoadjuvant 
chemotherapy (NACT) had distinct microRNA profiles and focused on microRNA 
molecules upregulated after NACT, hypothesizing that those microRNA molecules were 
necessary for chemotherapy resistance. They specifically studied miR-199, miR-29, miR-30, 
let-7, and miR-181 family members, as they were upregulated by QPCR in after NACT 
samples and associated with platinum resistance in other studies. MiR-199a-5p, 
miR-199a-3p, let-7a-5p, let-7g-5p, and miR-181a-5p were associated with worse 
progression-free survival. MiR-199a-5p, miR-199a-3p, miR-199b-5p, let-7g-5p, and 
miR-181a-5p were associated with worse overall survival. Multivariate analysis showed only 
let-7g-5p associated with overall survival with a hazard ratio of 1.1 (1.04–1.23) (59). 
Examination of P-SMAD2, an indirect target for miR-181a-5p, revealed a significant effect 
(hazard ratio 1.1 CI 1.0–1.2) on overall survival. Thus, these microRNA molecules and 
indirect targets may represent biomarkers of platinum resistance in a very specific group of 
patients. A potential concern, however, is represented by the rather modest hazard ratio, 
pointing to the need for large cohorts in any future validation study. Similar to studies in 
breast cancer, high expression of miR-622 in EOC was associated with loss of ku protein 
from the homologous recombination pathway and poor outcome. This suggests that 
miR-622 was associated with resistance to chemotherapy including poly ADP ribose 
polymerase (PARP) inhibitors (60). Since PARP inhibitors are now FDA approved for 
ovarian cancer therapy (61), this microRNA marker may be an additional marker useful for 
selecting appropriate candidates for this particular therapy.
e. Hypoxia Regulated MiRNA Molecules in EOC
Hypoxia plays an important role in microRNA molecule biogenesis and clinical oncology 
poor outcomes (62, 63). Hypoxia is important for DICER and DROSHA downregulation in 
EOC (64). Rupaimoole et al (64) found that hypoxic conditions downregulated DICER and 
DROSHA expression in vitro and in vivo. The expression levels of DICER and DROSHA 
and a panel of hypoxia markers showed an inverse correlation in EOC. Additionally, these 
studies revealed global microRNA downregulation following exposure to hypoxia. 
Examination of survival with a hypoxia metagene signature in TCGA datasets revealed an 
association of poor survival with high levels of hypoxia (64). MiR-199a-3p, miR-216b, 
miR-548d-5p, and miR-579 were found downregulated and 19 miRNAs were upregulated in 
ovarian cancer under hypoxia (65). Overexpression of miR-199a-3p reduces the invasion of 
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ovarian cancer cells in response to hypoxia (65). The role of hypoxia in microRNA molecule 
expression and function in EOC deserves additional study.
5. MicroRNA Molecules as Therapy for EOC
Given the ability of specific microRNA molecules to sensitize tumors to chemotherapy in 
vitro, studies have used microRNA molecules as adjuvant therapy with microRNA 
molecules in xenograft mouse models (Table 2). AntagomiR MiR-1307 treatment of mice 
with xenograft tumors resulted in a decrease in tumor size and an even further decrease in 
tumor size with paclitaxel treatment (66). Treatment of xenograft mouse models with 
miR-192-DOPC (1,2-dioleoyl-sn-glycero-3-phosphocholine) leads to inhibition of 
angiogenesis and tumor growth (67). MiR-551b-3p is located in a genomic region frequently 
amplified in high-grade serous EOC (68). MiR-551b-3p overexpression in high-grade EOC 
is associated with decreased overall survival. Interestingly, miR-551-3p binds to the 
promoter of signal transducer and activator of transcription 3 (STAT3), leading to increased 
expression of STAT3. Treatment of mouse models with anti-miR-551b-3p via a liposomal 
delivery system decreased tumor burden in vivo (69). These few pre-clinical models show 
promise for treatment of EOC with molecules that regulate microRNA expression.
6. Challenges to Clinical Use of MicroRNA Molecules and MicroRNA-
Regulatory Machinery in EOC
MicroRNA molecules hold promise as biomarkers for clinical associations, early markers 
for disease, and adjuvant therapy. However, most of the corresponding studies have yet to be 
replicated. Studies using biological fluids such as urine, serum, or plasma need to consider 
details such as phase of the menstrual cycle, effect of exogenous hormones or bioidentical 
compounds, type of sample collection, and processing of samples. The reference range or 
control group needs to be considered carefully. EOC as a disease arising from the ovary has 
been challenged. Many studies have compared EOC to normal ovarian epithelium, but the 
cell of origin for high-grade serous EOC may be fallopian tube epithelium. Limited studies 
on the more rare subtypes of EOC, such as endometrioid, clear-cell, or mucinous, need to be 
addressed because understanding the differences may lead to improved therapy for specific 
histotypes or specific molecular characteristics – possibly based on microRNA molecule 
expression. Treatment of patients with microRNA molecules needs further study in drug 
delivery and microRNA effects. However, these pre-clinical studies hold promise for the 
future.
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Highlights
• Expression of microRNA-regulatory machinery may serve as unique 
biomarkers for prognosis in epithelial ovarian cancer
• MicroRNA molecules are promising biomarkers for epithelial ovarian cancer
• MicroRNA molecules are promising therapeutic adjuvants for epithelial 
ovarian cancer
• Further work is needed to understand the molecular mechanisms of 
microRNA molecules in subtypes of epithelial ovarian cancer
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Table 2
In vivo mouse models of miRNA therapy in epithelial ovarian cancer
miRNA
Treatment
Method Effect Ref
miR-1307 A2780 cells subcutaneous injection Chemotherapy sensitivity (Taxol) (66)
miR-192 SKOV3ip1 cells intraperitoneal injection Tumor growth (67)
miR-506 HeyA8-IP2 and SKOV3-IP1 cells intraperitoneal 
injection
Invasion Metastasis Chemotherapy sensitivity (cisplatin 
and olaparib)
(76, 77)
miR-551b-3p IGROV1 or HEYA8 cells intraperitoneal injection Tumor growth Ascites formation (69)
miR-6126 HeyA8 cells intraperitoneal injection Tumor growth Angiogenesis (78)
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